Sionna Therapeutics, Inc. Common Stock SION
Analyst Ratings
- Consensus
- Moderate Buy — 5 Buy · 4 Hold · 1 Sell (10 analysts)
- Avg. Price Target
- $43.38 (+729.3% upside)
Key Stats
- Today's Range
- $5.15 – $5.59
- 50-Day Range
- $4.01 – $54.97
- 52-Week Range
- $4.01 – $54.97
- Volume
- 1.25 million shs
- Average Volume
- 1.79 million shs
- Market Cap
- $236.46 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 0.89
- Price / Sales
- —
Short Interest
- Short Interest
- 1.39%
- Days to Cover
- 2.09
Financials (TTM)
- Revenue
- —
- Net Income
- $-97,383,000
- Net Margin
- —
- Return on Equity
- -36.64%
- Debt-to-Equity
- —
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Related Stocks
Compare head-to-head: SION vs LLY·SION vs JNJ·SION vs ABBV·SION vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.